Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-20T02:16:26.364Z Has data issue: false hasContentIssue false
  • English
  • Français

Cerebrospinal fluid somatostatin in delirium. II Changes at the acute stage and at one year follow-up

Published online by Cambridge University Press:  09 July 2009

Hannu Koponen ,
Kari Reinikainen  and
Paavo J. Riekkinen
Hannu Koponen*
Affiliation:
Departments of Psychiatry and Neurology, Kuopio University Central Hospital, Kuopio, Finland
Kari Reinikainen
Affiliation:
Departments of Psychiatry and Neurology, Kuopio University Central Hospital, Kuopio, Finland
Paavo J. Riekkinen
Affiliation:
Departments of Psychiatry and Neurology, Kuopio University Central Hospital, Kuopio, Finland
*
1Address for correspondence: Dr Hannu Koponen, Kölikaari 29 C 35, SF-50170 Mikkeli, Finland.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Cerebrospinal fluid somatostatin-like immunoreactivity (CSF SLI) was determined for elderly delirious patients during the acute stage and after one-year follow-up. The SLI levels were compared with age-equivalent controls. For the group as a whole, and also when the group was subdivided according to the severity of cognitive decline at the acute stage, type of delirium, or the central nervous system disease, delirious patients showed significant reduction of SLI as compared with the controls. In the follow-up, we observed a further reduction of CSF SLI together with significant correlations in the second and third samples between SLI levels and Mini-Mental State Examination score. Our results suggest a role for somatostatinergic dysfunction in the genesis of some symptoms of delirium. This dysfunction may be a common phenomenon in various forms of delirium and dementia.

Type
Original Articles
Information
Psychological Medicine , Volume 20 , Issue 3 , August 1990 , pp. 501 - 505
Copyright
Copyright © Cambridge University Press 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental Disorders (3rd edn). APA: Washington, DC.Google Scholar
Aronin, N., Cooper, P. E., Lorentz, L. J., Bird, E. D., Sagar, S. M., Leeman, S. E. & Martin, J. B. (1983). Somatostatin is increased inthe basul ganglia in Huntington disease. Annals of Neurology 13, 519–526.CrossRefGoogle Scholar
Beal, M. F. & Martin, J. B. (1986). Neuropeptides in neurological disease. Annals of Neurology 20, 547–565.CrossRefGoogle ScholarPubMed
Beal, M. F., Mazurek, M. F., Black, P. McL. & Martin, J. B. (1985). Human cerebrospinal fluid somatostatin in neurologic disease. Journal of the Neurological Sciences 71, 91–104.CrossRefGoogle ScholarPubMed
Beal, M. F., Growdon, J. H., Mazurek, M. F. & Martin, J. B. (1986). CSF somatostatin-like immunoreactivity in dementia. Neurology 36, 294–297.CrossRefGoogle ScholarPubMed
Bissette, G., Widerlöv, E., Walleus, H., Karlsson, I., Eklund, K., Loosen, P. T. & Nemeroff, C. B. (1986). Alterations in cerebrospinal fluid concentrations of somatostatin-like immuno-reactivity in neuropsychiatric disorders. Archives of General Psychiatry 43, 1148–1151.CrossRefGoogle Scholar
Cramer, H., Schaudt, D., Rissler, K., Strubel, D., Warter, J.-M. & Kuntzman, F. (1985 a). Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. Journal of Neurology 232, 346–351.CrossRefGoogle ScholarPubMed
Cramer, H., Wolf, A., Rissler, K., Weigel, K. & Ostertag, C. (1985 b). Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease. Journal of Neurology 232, 219–222.CrossRefGoogle ScholarPubMed
Davies, P. & Terry, R. D. (1981). Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiology of Aging 2, 9–14.CrossRefGoogle ScholarPubMed
Duara, R., Grady, C., Haxby, J., Sundaram, M., Cutler, N. R., Heston, L., Moore, A., Schlageter, N., Larson, S. & Rapoport, S. I. (1986). Positron emission tomography in Alzheimer's disease. Neurology 36, 879–887.CrossRefGoogle ScholarPubMed
Dupont, E., Christensen, S. E., Hansen, A. P., Olivarius, B. F. & Orskov, H. (1982). Low cerebrospinal fluid somatostatin in Parkinson's disease: an irreversible abnormality. Neurology 32, 312–314.CrossRefGoogle ScholarPubMed
Folstein, M. F., Folstein, S. E. & McHugh, P. R. (1975). ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189–198.CrossRefGoogle Scholar
Francis, P. T., Bowen, D. M., Neary, D., Palo, J., Wikstrom, J. & Olney, J. (1984). Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiology of Aging 5, 183–186.CrossRefGoogle ScholarPubMed
Gattaz, W. F., Rissler, K., Gattaz, D. & Cramer, H. (1986). Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of schizophrenic patients. Psychiatric Research 17, 1–6.CrossRefGoogle ScholarPubMed
Hoehn, M. M. & Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology 17, 427–442.CrossRefGoogle ScholarPubMed
Jolkkonen, J., Soininen, H., Halonen, T., Ylinen, A., Laulumaa, V., Laakso, M. & Riekkinen, P. J. (1986). Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. Journal of Neurology, Neurosurgery and Psychiatry 49, 1374–1377.CrossRefGoogle ScholarPubMed
Jolkkonen, J., Pitkänen, A., Riekkinen, P. J., Korpi, E. R., Kaufman, C. A. & Weinberger, D. R. (1989). Decreased somatostatin-like immunoreactivity in CSF of schizophrenic patients during haloperidol treatment. Submitted to Psychoneuroendocrinology.Google Scholar
Kohler, J., Schröter, E. & Cramer, H. (1982). Somatostatin-like immunoreactivity in the cerebrospinal fluid of neurological patients. Archives of Psychiatry and Neurological Sciences 231, 503–508.Google ScholarPubMed
Koponen, H., Stenbäck, U., Mattila, E., Reinikainen, K., Soininen, H. & Riekkinen, P. J. (1989 a). Cerebrospinal fluid somatostatin in delirium. Psychological Medicine 19, 605–609.CrossRefGoogle ScholarPubMed
Koponen, H., Stenbäck, U., Mattila, E., Soininen, H., Reinikainen, K. & Riekkinen, P. J. (1989 b). Delirium among elderly persons admitted to a psychiatric hospital: clinical course during the acute stage and one year follow-up. Acta Psvchiatrica Scandinavica 79, 579–585.CrossRefGoogle ScholarPubMed
Lipowski, Z. J. (1980). Delirium: Acute Brain Failure in Man. Charles C. Thomas: Springfield.Google Scholar
Lipowski, Z. J. (1983). Transient cognitive disorders (delirium, acute confusional states) in the elderly. American Journal of Psychiatry 140, 1426–1436.Google ScholarPubMed
Lipowski, Z. J. (1987). Delirium (acute confusional states). Journal of the American Medical Association 258, 1789–1792.CrossRefGoogle ScholarPubMed
Lishman, A. W. (1987). Organic Psychiatry. Blackwell Scientific Publications: Oxford.Google Scholar
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. & Sladlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939–944.CrossRefGoogle ScholarPubMed
Mesulam, M.-M. (1986). Principles of Behavioral Neurology. F. A. Davis: Philadelphia.Google Scholar
Perez, E. L. & Silverman, M. (1984). Delirium: the often overlooked diagnosis. International Journal of Psychiatry in Medicine 14, 181–189.CrossRefGoogle Scholar
Reinikainen, K. & Riekkinen, P. J. (1989). Noncholinergic neu-rotransmitter markers in the CSF of patients with dementia of Alzheimer type. In Biological Markers in Dementia of Alzheimer Type (ed. Fowler, J. C., Carlson, L. A., Gottfries, C.-G. & Winblad, B.), pp. 161–178. Smith-Gordon: London.Google Scholar
Reinikainen, K. J., Riekkinen, P. J., Jolkkonen, J., Kosma, V.-M. & Soininen, H. (1987). Decreased somatostatin-like immuno-reactivity in cerebral cortex and cerebrospinal fluid in Alzheimer's disease. Brain Research 402, 103–108.CrossRefGoogle Scholar
Rubinow, D. R., Gold, P. W., Post, R. M., Ballenger, J. C., Cowdry, R., Bollinger, J. & Reichlin, S. (1983). CSF somatoslatin in affective illness. Archives of General Psychiatry 40, 409–412.CrossRefGoogle ScholarPubMed
Rubinow, D. R., Post, R. M., Gold, P. W., Ballenger, J. C. & Reichlin, S. (1985). Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology 85, 210–213.CrossRefGoogle ScholarPubMed
Soininen, H. S., Jolkkonen, J. T., Reinikainen, K. J., Halonen, T. O. & Riekkinen, P. J. (1984). Reduced cholineslerase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of Alzheimer type. Journal of the Neurological Sciences 63, 167–172.CrossRefGoogle Scholar
Sunderland, T., Rubinow, D. R., Tariot, P. N., Cohen, R. M., Newhouse, P. A., Mellow, A. M., Mueller, E. A. & Murphy, D. L. (1987). CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. American Journal of Psychiatry 144, 1313–1316.Google ScholarPubMed
Tamminga, C. A., Foster, N. L., Fedio, P., Bird, E. D. & Chase, T. N. (1987). Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37, 161–165.CrossRefGoogle ScholarPubMed
Trzepacz, P. T., Teague, G. B. & Lipowski, Z. J. (1985). Delirium and other organic mental disorders in a general hospital. General Hospital Psychiatry 7, 101–106.CrossRefGoogle ScholarPubMed